Stemline Therapeutics (NASDAQ:STML) Earns “Buy” Rating from Cowen

Cowen reaffirmed their buy rating on shares of Stemline Therapeutics (NASDAQ:STML) in a research note published on Wednesday morning, AnalystRatings.com reports.

STML has been the subject of a number of other reports. BidaskClub lowered Stemline Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, September 10th. Wedbush raised Stemline Therapeutics from a neutral rating to an outperform rating in a research note on Friday, August 2nd. Zacks Investment Research lowered Stemline Therapeutics from a buy rating to a hold rating in a research note on Wednesday, August 7th. HC Wainwright set a $35.00 price target on Stemline Therapeutics and gave the company a buy rating in a research note on Thursday, June 20th. Finally, ValuEngine lowered Stemline Therapeutics from a buy rating to a hold rating in a research note on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Stemline Therapeutics presently has a consensus rating of Buy and a consensus price target of $23.50.

Shares of Stemline Therapeutics stock opened at $11.14 on Wednesday. The stock has a 50 day moving average of $13.10 and a 200 day moving average of $13.73. Stemline Therapeutics has a 12 month low of $7.82 and a 12 month high of $18.22. The firm has a market cap of $508.13 million, a PE ratio of -3.73 and a beta of 1.39. The company has a current ratio of 4.71, a quick ratio of 4.57 and a debt-to-equity ratio of 0.01.



Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Friday, August 2nd. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.05. The firm had revenue of $13.01 million for the quarter, compared to the consensus estimate of $8.84 million. As a group, equities research analysts forecast that Stemline Therapeutics will post -1.92 earnings per share for the current fiscal year.

In other news, COO Kenneth Hoberman sold 9,107 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $15.49, for a total value of $141,067.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ivan Bergstein sold 56,316 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $15.08, for a total value of $849,245.28. The disclosure for this sale can be found here. Insiders sold a total of 158,370 shares of company stock valued at $2,383,666 over the last ninety days. Corporate insiders own 13.10% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Nuveen Asset Management LLC bought a new stake in shares of Stemline Therapeutics in the 2nd quarter valued at approximately $1,968,000. OneAscent Financial Services LLC bought a new stake in shares of Stemline Therapeutics in the 2nd quarter valued at approximately $175,000. Citadel Advisors LLC lifted its stake in shares of Stemline Therapeutics by 2,681.4% in the 2nd quarter. Citadel Advisors LLC now owns 357,411 shares of the biopharmaceutical company’s stock valued at $5,476,000 after purchasing an additional 344,561 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Stemline Therapeutics by 196.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 518,870 shares of the biopharmaceutical company’s stock valued at $7,949,000 after purchasing an additional 343,870 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Stemline Therapeutics by 14.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,933,455 shares of the biopharmaceutical company’s stock valued at $29,620,000 after purchasing an additional 237,768 shares during the last quarter. 82.46% of the stock is owned by institutional investors and hedge funds.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Further Reading: What is an economic bubble?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.